Key result
Proton pump inhibitors fail to reduce upper gastrointestinal bleeding in severe stroke patients.
Why the study?
The relationship between proton pump inhibitor use and upper gastrointestinal bleeding in critically ill severe stroke patients was unclear, and a predictive model for mortality was needed.
Cohort (n=5,716)
No
PPI use was not associated with lower UGIB risk in severe stroke; leaves open whether randomized trials should alter prophylaxis practices.
GOALS: We aim to explore the relationship between the use of proton pump inhibitors (PPIs) and upper gastrointestinal bleeding (UGIB). We develop a nomogram model to predict mortality in critically ill stroke patients. STUDY: This is a retrospective study based on the MIMIC IV database. We extracted clinical information including demographic data, comorbidities, and laboratory indicators. Univariate and multivariable logistic regressions were used to assess and identify risk factors for the occurrence of UGIB and for the in-hospital mortality of critically ill stroke patients. The resulting model was used to construct a nomogram for predicting in-hospital mortality. RESULTS: Five thousand seven hundred sixteen patients from the MIMIC-IV database were included in our analysis. UGIB occurred in 109 patients (1.9%), whereas the PPI use rate was as high as 60.6%. Chronic liver disease, sepsis, shock, anemia, and increased level of urea nitrogen were independent risk factors for the occurrence of UGIB in severe stroke patients. We identified age, heart failure, shock, coagulopathy, mechanical ventilation, continuous renal replacement therapy, antiplatelet drugs, anticoagulation, simplified acute physiology score-II, and Glasgow coma score as independent risk factors for in-hospital mortality in severe stroke patients. The C-index for the final nomograms was 0.852 (95% confidence interval: 0.840, 0.864). CONCLUSIONS: We found that the overall rate of UGIB in severe stroke patients is low, whereas the rate of PPI usage is high. In our study, PPI was not identified as a risk factor for the occurrence of UGIB and UGIB was not associated with all-cause mortality. More clinical trials are needed to evaluate the benefits of using PPI in critically ill stroke patients.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2023) conducted a cohort in Acute severe cerebral stroke (n=5,716). Proton pump inhibitors (PPIs) vs. Non-PPI use was evaluated on Occurrence of upper gastrointestinal bleeding (UGIB) (OR 0.820, 95% CI 0.551, 1.220, p=0.327). In critically ill patients with severe stroke, the use of proton pump inhibitors was not significantly associated with the occurrence of upper gastrointestinal bleeding (OR 0.820).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: